{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:10Z","timestamp":1791252790520,"version":"4.1.0"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2526,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1002\/hep.22506","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T16:26:44Z","timestamp":1215534404000},"page":"1312-1327","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":852,"title":["Molecular targeted therapies in hepatocellular carcinoma\u2020"],"prefix":"10.1097","volume":"48","author":[{"given":"Josep M.","family":"Llovet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-33-20241201","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-33-20241201","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El Serag","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-33-20241201","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1055\/s-2005-871194","article-title":"Hepatocellular carcinoma: epidemiology, risk factors, and screening","volume":"25","author":"Sherman","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R4-33-20241201","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R5-33-20241201","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R6-33-20241201","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R7-33-20241201","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R8-33-20241201","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2\u2010positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"R9-33-20241201","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R10-33-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2010small\u2010cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-33-20241201","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrc1934","article-title":"Hepatocellular carcinoma pathogenesis: from genes to environment","volume":"6","author":"Farazi","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R12-33-20241201","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/ng0802-339","article-title":"Molecular pathogenesis of human hepatocellular carcinoma","volume":"31","author":"Thorgeirsson","year":"2002","journal-title":"Nat Genet"},{"key":"R13-33-20241201","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1535-6108(04)00058-3","article-title":"Focus on hepatocellular carcinoma","volume":"5","author":"Bruix","year":"2004","journal-title":"Cancer Cell"},{"key":"R14-33-20241201","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-2006-960171","article-title":"Genes and signaling pathways involved in the pathogenesis of HCC","volume":"27","author":"Villanueva","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R15-33-20241201","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/hep.21196","article-title":"Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma","volume":"43","author":"Branda","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R16-33-20241201","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1038\/sj.onc.1206528","article-title":"Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers","volume":"22","author":"Ferber","year":"2003","journal-title":"Oncogene"},{"key":"R17-33-20241201","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.onc.1210279","article-title":"TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer","volume":"26","author":"Hussain","year":"2007","journal-title":"Oncogene"},{"key":"R18-33-20241201","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"R19-33-20241201","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"R20-33-20241201","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of HCC","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"key":"R21-33-20241201","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm1377","article-title":"A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells","volume":"12","author":"Lee","year":"2006","journal-title":"Nat Med"},{"key":"R22-33-20241201","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R23-33-20241201","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/0008-5472.CAN-04-0292","article-title":"Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin\u2010like growth factor II overexpression","volume":"64","author":"Breuhahn","year":"2004","journal-title":"Cancer Res"},{"key":"R24-33-20241201","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ccr.2006.06.016","article-title":"Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment","volume":"10","author":"Budhu","year":"2006","journal-title":"Cancer Cell"},{"key":"R25-33-20241201","first-page":"5021","article-title":"Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma","volume":"63","author":"Farazi","year":"2003","journal-title":"Cancer Res"},{"key":"R26-33-20241201","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1055\/s-2005-871200","article-title":"Hepatocellular carcinoma: molecular pathways and new therapeutic targets","volume":"25","author":"Roberts","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R27-33-20241201","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"R28-33-20241201","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"R29-33-20241201","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous\u2010cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"R30-33-20241201","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the treatment of colorectal cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N Engl J Med"},{"key":"R31-33-20241201","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2\u2010positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"R32-33-20241201","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","article-title":"Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC","volume":"130","author":"Calvisi","year":"2006","journal-title":"Gastroenterology"},{"key":"R33-33-20241201","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R34-33-20241201","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.20969","article-title":"Liver regeneration","volume":"43","author":"Fausto","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R35-33-20241201","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.1158\/0008-5472.CAN-07-1905","article-title":"Loss of hepatocyte growth factor\/c\u2010Met signaling pathway accelerates early stages of N\u2010nitrosodiethylamine induced hepatocarcinogenesis","volume":"67","author":"Takami","year":"2007","journal-title":"Cancer Res"},{"key":"R36-33-20241201","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors:targeting oncogene addition and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"R37-33-20241201","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin\u2010like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"R38-33-20241201","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1038\/sj.onc.1209556","article-title":"Dysregulation of growth factor signaling in human hepatocellular carcinoma","volume":"25","author":"Breuhahn","year":"2006","journal-title":"Oncogene"},{"key":"R40-33-20241201","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R41-33-20241201","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jhep.2007.08.018","article-title":"Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection","volume":"48","author":"Schmitz","year":"2008","journal-title":"J Hepatol"},{"key":"R43-33-20241201","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg1427","article-title":"WNT and beta\u2010catenin signalling: diseases and therapies","volume":"5","author":"Moon","year":"2004","journal-title":"Nat Rev Genet"},{"key":"R44-33-20241201","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1053\/gast.2001.24798","article-title":"Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis","volume":"120","author":"Laurent\u2010Puig","year":"2001","journal-title":"Gastroenterology"},{"key":"R45-33-20241201","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4161\/cbt.5.2.2566","article-title":"Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC","volume":"5","author":"Osipo","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"R46-33-20241201","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI34359","article-title":"To kill a tumor cell: the potential of proapoptotic receptor agonist","volume":"118","author":"Ashkenazi","year":"2008","journal-title":"J Clin Invest"},{"key":"R47-33-20241201","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jhep.2008.01.008","article-title":"Experimental models in hepatocellular carcinoma","volume":"48","author":"Newell","year":"2008","journal-title":"J Hepatol"},{"key":"R48-33-20241201","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/ng1481","article-title":"Application of comparative functional genomics to identify best\u2010fit mouse models to study human cancer","volume":"36","author":"Lee","year":"2004","journal-title":"Nat Genet"},{"key":"R49-33-20241201","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1073\/pnas.0409722102","article-title":"Platelet\u2010derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma","volume":"102","author":"Campbell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R50-33-20241201","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-2005-871198","article-title":"Resection and liver transplantation for hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R51-33-20241201","first-page":"17A","article-title":"Treatment of advanced hepatocellular carcinoma by seocalcitol: an international randomized double\u2010blind placebo\u2010controlled study in 747 patients","volume":"42","author":"Beaugrand","year":"2003","journal-title":"J Hepatol"},{"key":"R52-33-20241201","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/j.1365-2036.2006.02932.x","article-title":"Up\u2010dated systematic review of randomized controlled trials in hepatocellular carcinoma. 2002\u20132005","volume":"23","author":"Lopez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R53-33-20241201","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":", on behalf of Panel of Experts in HCC. Design and end\u2010points of clinical trials in HCC","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R54-33-20241201","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2010carboplatin alone or with bevacizumab for non\u2010small\u2010cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"R55-33-20241201","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"R56-33-20241201","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"R57-33-20241201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear\u2010cell renal\u2010cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R58-33-20241201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal\u2010cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R59-33-20241201","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal\u2010cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R60-33-20241201","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma","volume":"24","author":"Abou\u2010Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"R63-33-20241201","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014the major drug targets of the twenty\u2010first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"R64-33-20241201","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1200\/JCO.2005.14.696","article-title":"Phase II study of Erlotinib (OSI\u2010774) in patients with advanced hepatocellular cancer","volume":"23","author":"Philip","year":"2005","journal-title":"J Clin Oncol"},{"key":"R65-33-20241201","doi-asserted-by":"crossref","first-page":"214s","DOI":"10.1200\/jco.2007.25.18_suppl.4567","article-title":"The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC)","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"R67-33-20241201","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.22829","article-title":"Cetuximab Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma","volume":"110","author":"Zhu","year":"2007","journal-title":"Cancer"},{"key":"R72-33-20241201","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.2005.04.9130","article-title":"Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma","volume":"24","author":"Zhu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R74-33-20241201","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/jco.2007.25.18_suppl.3546","article-title":"Assessment of safety and drug\u2010induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC)","volume":"25","author":"Faivre","year":"2007","journal-title":"J Clin Oncol"},{"key":"R76-33-20241201","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd2089","article-title":"Strategies for optimizing combinations of molecularly targeted anticancer agents","volume":"5","author":"Dancey","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R77-33-20241201","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1124","article-title":"Rethinking clinical trials for cytostatic drugs","volume":"3","author":"Millar","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"R78-33-20241201","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J Hepatol"},{"key":"R79-33-20241201","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1056\/NEJMoa051918","article-title":"Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors","volume":"353","author":"Mellinghoff","year":"2005","journal-title":"N Engl J Med"},{"key":"R80-33-20241201","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/CCO.0b013e328302c9e9","article-title":"Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps","volume":"20","author":"Villanueva","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"R81-33-20241201","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMsb050564","article-title":"Medicare and cost\u2010effectiveness analysis","volume":"353","author":"Neumann","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200810000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:19:28Z","timestamp":1733055568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200810000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22506","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}